Novocure Reports 18 Presentations on Tumor-Treating Fields at SNO '15

Novocure

, a commercial stage oncology company, announced today that a record number of abstracts focusing on Tumor Treating Fields (TTFields) were accepted and will be presented at the 20th Annual Meeting of the Society for Neuro-Oncology on Nov. 19-22 in San Antonio, including oral presentations of two new analyses of the EF-14 superiority data for Optune in combination with temozolomide for the treatment of newly diagnosed glioblastoma (GBM). TTFields are low-intensity, intermediate frequency, alternating electric fields that inhibit cancer cell replication, leading to cancer cell death. TTFields therapy is administered by a portable, non-invasive medical device designed for continuous use by patients. "There will be 18 presentations on TTFields at SNO this year, a record for Novocure," said Eilon Kirson, Novocure's Chief Science Officer and Head of Research and Development. "This growing interest from the scientific community points to the strength of the EF-14 data and the potential for TTFields to treat a variety of solid tumors." The conference will include two oral abstract presentations with additional data from the EF-14 trial of Optune in combination with temozolomide for newly diagnosed GBM. One presentation will focus on quality of life and will show that the use of TTFields therapy with temozolomide did not adversely affect newly diagnosed patients' quality of life, cognitive and functional capabilities, and day-to-day living. The second presentation will focus on the survival benefit of TTFields after recurrence and will show that EF-14 patients who continued TTFields therapy in combination with chemotherapy, including bevacizumab, at first recurrence lived longer than patients who received chemotherapy alone. These analyses reaffirm the growing body of evidence demonstrating the superiority of TTFields in combination with temozolomide for the treatment of newly diagnosed GBM, and support Novocure's goal to establish Optune as a standard of care for newly diagnosed glioblastoma. "The EF-14 phase 3 data show that GBM patients who use Optune in combination with temozolomide live longer, higher quality lives than patients who don't receive TTFields therapy," said Asaf Danziger, Novocure's Chief Executive Officer. "Optune offers hope to a growing number of cancer patients and their families."